USA

The company has announced plans to expand its antibody-drug conjugate (ADC) manufacturing capabilities in Switzerland while also broadening its long-term partnership with a leading, though undisclosed, U.S.-based biopharmaceutical company.

The combined business will operate as Cortigent Holdings and trade on Nasdaq under the ticker symbol CRGT once the transaction closes, expected in the third quarter of 2026, subject to shareholder and regulatory approvals.

Researchers can use the platform to design CRISPR screening experiments, analyse single-cell RNA sequencing data and generate three-dimensional protein structures, chemistry drawings and genome browser tracks.

The agreement brings together Lilly’s expertise in developing innovative medicines with Abu Dhabi’s advanced healthcare infrastructure, population-scale health data, and genomics capabilities.

The new site will serve as the company’s U.S. global headquarters and future manufacturing centre as it accelerates the development of targeted cancer therapies.

Biogen has paused or discontinued funding for most of Apellis’ legacy research portfolio while conducting a comprehensive review of the acquired company’s clinical and preclinical assets.

Developed by Geneoscopy and offered commercially through Labcorp, ColoSense is intended for adults aged 45 to 85 years who are considered to have an average risk of colorectal cancer.

The acquisition gives Zymeworks access to Yupelri, an FDA-approved, once-daily nebulized maintenance therapy for chronic obstructive pulmonary disease (COPD) that Theravance markets in partnership with Viatris.

Gavi has indicated that proposals involving vaccine production in Africa will receive particular consideration as part of broader efforts to strengthen regional manufacturing capacity.

The announcement came during Moderna’s Science Day, where the biotechnology company outlined plans to broaden its pipeline across oncology, rare diseases, and immune-mediated disorders.